Sean Anthony Eddy/E+ via Getty Images Roche (OTCQX:RHHBY)(OTCQX:RHHBF)(OTCPK:RHHVF) still has good long-term prospects since the last time I wrote an article about it. This was with respect to an article entitled "Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender". In this article, I noted that this company had good long-term value with Ocrevus, which has been approved to treat patients with multiple sclerosis [MS]. Plus, that it was working on another drug for its pipeline, known ...